Decitabin

Decitabin
Klinički podaci
Drugs.comMonografija
Način primeneIntravenozno
Identifikatori
CAS broj2353-33-5 Зелена квачицаДа
ATC kodNone
PubChemCID 451668
DrugBankDB01262 Зелена квачицаДа
ChemSpider397844 Зелена квачицаДа
ChEBICHEBI:50131 Зелена квачицаДа
ChEMBLCHEMBL1201129 Зелена квачицаДа

Decitabin je organsko jedinjenje, koje sadrži 8 atoma ugljenika i ima molekulsku masu od 228,205 Da.[1][2][3][4][5][6][7][8][9]

Osobine

Osobina Vrednost
Broj akceptora vodonika 7
Broj donora vodonika 3
Broj rotacionih veza 2
Particioni koeficijent[10] (ALogP) -1,1
Rastvorljivost[11] (logS, log(mol/L)) -0,2
Polarna površina[12] (PSA, Å2) 120,7

Reference

  1. ^ Appleton K, Mackay HJ, Judson I, Plumb JA, McCormick C, Strathdee G, Lee C, Barrett S, Reade S, Jadayel D, Tang A, Bellenger K, Mackay L, Setanoians A, Schatzlein A, Twelves C, Kaye SB, Brown R: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. Appleton, K.; MacKay, H. J.; Judson, I.; Plumb, J. A.; McCormick, C.; Strathdee, G.; Lee, C.; Barrett, S.; Reade, S.; Jadayel, D.; Tang, A.; Bellenger, K.; MacKay, L.; Setanoians, A.; Schätzlein, A.; Twelves, C.; Kaye, S. B.; Brown, R. (2007 Oct 10). „Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors”. J Clin Oncol. 25 (29): 4603—9. PMID 17925555. doi:10.1200/JCO.2007.10.8688.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  2. ^ Wijermans PW, Ruter B, Baer MR, Slack JL, Hussain SI, Lubbert M: Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res. 2007 Sep 17;. Wijermans, P. W.; Rüter, B.; Baer, M. R.; Slack, J. L.; Saba, H. I.; Lübbert, M. (2008). „Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)”. Leukemia Research. 32 (4): 587—591. PMID 17881052. doi:10.1016/j.leukres.2007.08.004. 
  3. ^ Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Daskalakis, M.; Blagitko-Dorfs, N.; Hackanson, B. (2010). „Decitabine”. Recent Results Cancer Res. Recent Results in Cancer Research. 184: 131—57. ISBN 978-3-642-01221-1. PMID 20072836. doi:10.1007/978-3-642-01222-8_10. 
  4. ^ Saba HI, Wijermans PW: Decitabine in myelodysplastic syndromes. Semin Hematol. 2005 Jul;42(3 Suppl 2):S23-31. Saba, H. I.; Wijermans, P. W. (2005). „Decitabine in myelodysplastic syndromes”. Seminars in Hematology. 42 (3 Suppl 2): S23—31. PMID 16015501. doi:10.1053/j.seminhematol.2005.05.009. 
  5. ^ Jabbour E, Issa JP, Garcia-Manero G, Kantarjian H: Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer. Jabbour, E.; Issa, J. P.; Garcia-Manero, G.; Kantarjian, H. (2008 Jun). „Evolution of decitabine development: Accomplishments, ongoing investigations, and future strategies”. Cancer. 112 (11): 2341—51. PMC 4784235 Слободан приступ. PMID 18398832. doi:10.1002/cncr.23463.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  6. ^ Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Stresemann, C.; Lyko, F. (2008 Jul 1). „Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine”. Int J Cancer. 123 (1): 8—13. PMID 18425818. doi:10.1002/ijc.23607.  Проверите вредност парамет(а)ра за датум: |date= (помоћ)
  7. ^ Oki Y, Aoki E, Issa JP: Decitabine--bedside to bench. Crit Rev Oncol Hematol. Oki, Y.; Aoki, E.; Issa, J. P. (2007 Feb). „Decitabine--bedside to bench”. Critical Reviews in Oncology/Hematology. 61 (2): 140—52. PMID 17023173. doi:10.1016/j.critrevonc.2006.07.010.  Проверите вредност парамет(а)ра за датум: |date= (помоћ). Epub 2006 Oct 4.
  8. ^ Knox, C.; Law, V.; Jewison, T.; Liu, P.; Ly, S.; Frolkis, A.; Pon, A.; Banco, K.; Mak, C.; Neveu, V.; Djoumbou, Y.; Eisner, R.; Guo, A. C.; Wishart, D. S. (2011). „DrugBank 3.0: A comprehensive resource for 'Omics' research on drugs”. Nucleic Acids Research. 39 (Database issue): D1035—D1041. PMC 3013709 Слободан приступ. PMID 21059682. doi:10.1093/nar/gkq1126. 
  9. ^ Wishart, David S.; Knox, Craig; Guo, An Chi; Cheng, Dean; Shrivastava, Savita; Tzur, Dan; Gautam, Bijaya; Hassanali, Murtaza (2008). „DrugBank: A knowledgebase for drugs, drug actions and drug targets”. Nucleic Acids Research. 36 (Database issue): D901—D906. PMC 2238889 Слободан приступ. PMID 18048412. doi:10.1093/nar/gkm958. 
  10. ^ Ghose, Arup K.; Viswanadhan, Vellarkad N.; Wendoloski, John J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragmental Methods: An Analysis of ALOGP and CLOGP Methods”. The Journal of Physical Chemistry A. 102 (21): 3762—3772. Bibcode:1998JPCA..102.3762G. doi:10.1021/jp980230o. 
  11. ^ Tetko, Igor V.; Tanchuk, Vsevolod Yu.; Kasheva, Tamara N.; Villa, Alessandro E. P. (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Journal of Chemical Information and Computer Sciences. 41 (6): 1488—1493. PMID 11749573. doi:10.1021/ci000392t. 
  12. ^ Ertl, Peter; Rohde, Bernhard; Selzer, Paul (2000). „Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties”. Journal of Medicinal Chemistry. 43 (20): 3714—3717. PMID 11020286. doi:10.1021/jm000942e. 

Literatura

Spoljašnje veze

Decitabin на Викимедијиној остави.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.